Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
NCT#03609021
(Click for More Info)
Patients previously enrolled in A011502 are eligible to be enrolled in this protocol using the A211601 Retrospective Consent.
Eligible for screening study DCP 001
The following protocols have consent changes requiring you to reconsent active patients (unless otherwise noted below).
MCC policy requires all reconsents be completed at the patient’s next scheduled office visit or within two weeks of MCC release of approved consent document, whichever is sooner.
(Please click the links for the available highlighted reconsents & letters.)
July 27th, 2021
-
-
-
EAA173 –
ALL Arm A (daratumumab) Patients
July 13th, 2021
- No consent changes requiring reconsents
July 6th, 2021
- A021502 – Arm1 patients receiving atezolizumab & SOC therapy
- A031501- Patient Letter and Physician Letter–ALL Patients
- GI004-Addendum–ALL patients currently receiving atezolizumab
- GY009–ALL patients currently receiving atezolizumab
- LU002 – ALL patients currently receiving atezolizumab
- LU005 – ALL patients currently receiving atezolizumab
- LU007 – ALL patients
- R1216 – ALL patients
- S1806 – ALL patients currently receiving atezolizumab
- S1914 – ALL patients currently receiving atezolizumab
- S1929-Treatment – ALL patients currently receiving atezolizumab
- S1933 – ALL patients currently receiving atezolizumab
June 23rd, 2021
- A021502 –Arm 1 Patients receiving atezolizumab and SOC therapy
June 15th, 2021
June 1st, 2021
May 18th, 2021
- No consent changes requiring reconsents
May 4th, 2021
- S1914 – ALL Active SBRT Patients
April 20th, 2021
- S1007– Addendum– ALL Patients who meet criteria in Section 5.3 of the protocol
April 6th, 2021
March 17th, 2021
- A071702 – ALL Patients treated with Nivolumab
- A031704– ALL Patients treated with Nivolumab
- A071702– ALL Patients treated with Nivolumab
- A091401 – ALL Patients treated with Nivolumab
- E4412 – ALL Patients treated with Nivolumab
- EA2165 – ALL Patients treated with Nivolumab
- EA2176 – ALL Patients treated with Nivolumab
- EA3161 – ALL Patients treated with Nivolumab
- EA5161 – ALL Patients treated with Nivolumab
- EA5191 – ALL Patients treated with Nivolumab
- EA6134 – ALL Patients treated with Nivolumab
- EA6141 – ALL Patients treated with Nivolumab
- EA8143– ALL Patients treated with Nivolumab
- S1400I – ALL Patients treated with Nivolumab
- S1609 – ALL Patients treated with Nivolumab
- S1616– ALL Patients treated with Nivolumab
- S1826 – ALL Patients treated with Nivolumab
March 16th, 2021
- No consent changes requiring reconsents.
March 2nd, 2021
February 16th, 2021
February 2nd, 2021
January 19th, 2021
- A071701 – ALL Active Patients
- S1933 – ALL Active Patients receiving radiation
January 5th, 2021
December 23rd, 2020
December 15th, 2020
- HN005-Phase II – Active Phase II patients receiving cisplatin (group 1 and group 2)
- S1900B – ALL Active Patients receiving selpercatinib (LOXO-292)
December 1st, 2020
November 17th, 2020
November 3rd, 2020
October 20th, 2020
October 6th, 2020
- EA2187–ALL Active Patients receiving Pevonedistat
- COVID–19-ALL Patients
- S1403–ALL Active Patients receiving afatinib
September 15th, 2020
September 1st, 2020
- No consent changes requiring reconsents.
August 19th, 2020
August 18th, 2020
August 4th, 2020
July 21st, 2020
- No consent changes requiring reconsents.
July 7th, 2020
June 16th, 2020
June 2nd, 2020
May 19th, 2020
May 7th, 2020
- No consent changes requiring reconsents.
May 5th, 2020
- No consent changes requiring reconsents.
April 23rd, 2020
- No consent changes requiring reconsents.
April 21st, 2020
April 7th, 2020
March 17th, 2020
March 3rd, 2020
February 26th, 2020 – CIRB
February 2020 – Local IRB
- No consent changes requiring reconsents.
February 14th, 2020 – CIRB
- No consent changes requiring reconsents.
January 29th, 2020 – CIRB
- No consent changes requiring reconsents.
January 2020 – Local IRB
- No consent changes requiring reconsents.
January 15th, 2020 – CIRB
January 2nd, 2020 – CIRB
December 2019 – Local IRB
December 16th, 2019 – CIRB
December 2nd, 2019 – CIRB
November 2019 – Local IRB
- No consent changes requiring reconsents.
November 15th, 2019 – CIRB
November 1st, 2019 – CIRB
October 2019 – Local IRB
- No consent changes requiring reconsents.
October 11th, 2019 – CIRB
October 4th, 2019 – CIRB
October 1st, 2019 – CIRB
September 2019 – Local IRB
- No consent changes requiring reconsents.
September 16th, 2019 – CIRB
September 3rd, 2019 – CIRB
August 2019 – Local IRB
- No consent changes requiring reconsents.
August 15th, 2019 – CIRB
August 1st, 2019 – CIRB
July 23rd, 2019 – CIRB
July 2019 – Local IRB
July 15th, 2019 – CIRB
July 1st, 2019 – CIRB
June 2019 – Local IRB
June 14th, 2019 – CIRB
May 31st, 2019 – CIRB
May 15th, 2019 – CIRB
May 1st, 2019 – CIRB
- No consent changes requiring reconsents.
April 26th, 2019 – CIRB
April 15th, 2019 – CIRB
April 2019 – Local IRB
- No consent changes requiring reconsents.
April 1st, 2019 – CIRB
- E1910 – Pts receiving Blinatumomab ONLY
March 15th, 2019 – CIRB
March 2019 – Local IRB
- No consent changes requiring reconsents.
March 1st, 2019 – CIRB
February 2019 – Local IRB
- No consent changes requiring reconsents.
February 15th, 2019 – CIRB
February 1st, 2019 – CIRB
January 2019 – Local IRB
- No consent changes requiring reconsents.
January 15th, 2019 – CIRB
January 2nd, 2019 – CIRB
[/members_only]
